Development of multi-lateral cancer gene therapy by enhancing anti-tumor activity of inactivated Sendai virus particle

我们已经报道了紫外线灭活的仙台病毒颗粒(日本包膜血凝病毒；HVJ-E)具有多种抗肿瘤活性。HVJ-E已经开始临床应用，以评估该颗粒在癌症患者中的安全性和有效性。为了增强抗肿瘤活性，我们尝试将治疗分子整合到HVJ-E中。因此，携带IL-2或IL-12基因的HVJ-E可增强小鼠的抗肿瘤免疫。我们研制了表面带有IL-12多肽的HVJ-E，其治疗黑色素瘤的效果比单独使用的HVJ-E更有效。RAD51 siRNA被整合到HVJ-E中，与抗肿瘤试剂Dacarbazine联合使用时，可以增强癌症的治疗效果。

We have reported that UV-inactivated Sendai virus particles (hemagglutinating virus of Japan envelope; HVJ-E) have multiple anti-tumor activities. Clinical application of HVJ-E has been started to evaluate the safety and efficacy of the particle in cancer patients. To enhance the anti-tumor activities, we attempted to incorporate therapeutic molecules into HVJ-E. As a result, HVJ-E containing IL2 or IL-12 gene enhanced anti-tumor immunity. HVJ-E having IL-12 polypeptide on the surface was developed and was more effective for the treatment of melanoma than original HVJ-E alone. Rad51 siRNA incorporated into HVJ-E augmented the effect of cancer treatment when combined with anti-tumor reagent, dacarbazine.